XY028-133
Code | Size | Price |
---|
TAR-T13361-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T13361-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
XY028-133 is a PROTAC-based CDK4/6 degrader, with anti-tumor activity.
CAS:
2229974-73-4
Formula:
C53H67N11O7S
Molecular Weight:
1002.23
Purity:
0.98
SMILES:
O=C1N(C=2C(C(C)=C1C(C)=O)=CN=C(NC3=CC=C(C=N3)N4CCN(C(CCCCCC(N[C@H](C(=O)N5[C@H](C(NCC6=CC=C(C=C6)C=7SC=NC7C)=O)C[C@@H](O)C5)[C@@](C)(C)C)=O)=O)CC4)N2)C8CCCC8
References
JIN, Jian? et al. COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER. Patent. US2017/065027.